|
Title
|
|
|
|
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV Types (PATRICIA Randomized Trial) : an unexpected observation
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Background. Public Health England has reported a decrease of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the national vaccination program with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began in 2008. A post hoc analysis of the phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed to ascertain whether protection against low-risk HPV types was apparent. Methods. Vaccine efficacy (VE) at 48 months was assessed against 6-month persistent infection (6MPI) with low-risk HPV types in the total vaccinated cohort (TVC) and in the TVC naive (for 25 HPV types tested) populations. Results. In the TVC naive cohort, VE against 6MPI (95% confidence interval) was 34.5% (11.3 to 51.8) for HPV6/11, 34.9% (9.1 to 53.7) for HPV-6, 30.3% (-45.0 to 67.5) for HPV-11, and 49.5% (21.0 to 68.3) for HPV-74. Conclusions. The HPV-16/18 AS04-adjuvanted vaccine appears to have moderate efficacy against persistent infections with a number of low-risk HPV types (HPV-6/11/74), which are responsible for the majority of external GWs, and recently, antibody and cell-mediated immune response to HPV-6/11 have been observed. These findings may help to explain the decrease in external GW diagnoses seen in England. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
The journal of infectious diseases. - Chicago, Ill.
|
|
|
Publication
|
|
|
|
Chicago, Ill.
:
2013
|
|
|
ISSN
|
|
|
|
0022-1899
|
|
|
DOI
|
|
|
|
10.1093/INFDIS/JIT360
|
|
|
Volume/pages
|
|
|
|
208
:9
(2013)
, p. 1391-1396
|
|
|
ISI
|
|
|
|
000326377500007
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|